Zobrazeno 1 - 3
of 3
pro vyhledávání: '"E. V. Gayazova"'
Autor:
V. N. Antonov, G. L. Ignatova, O. V. Pribytkova, S. S. Sleptsova, E. A. Strebkova, E. A. Khudyakova, A. I. Simakov, S. Yu. Rabets, E. P. Tikhonova, D. Yu. Kurmaeva, M. A. Petrushin, A. S. Mashkov, E. V. Gayazova, I. V. Yasheva, M. A. Andreev, V. V. Khinovker, A. Yu. Karpunin, B. V. Berezhanskiy
Publikováno v:
Терапевтический архив, Vol 92, Iss 12, Pp 148-154 (2020)
Most subjects with the COVID-19 experience mild to moderate symptoms, but approximately 10% of cases suffer from severe course of disease. IL-6 inhibitors are actively used to neutralize and prevent the cytokine storm. Olokizumab is a humanized monoc
Externí odkaz:
https://doaj.org/article/96ee8408d2e544349bcfd83fcc37fe4a
Publikováno v:
Неврология, нейропсихиатрия, психосоматика, Vol 7, Iss 4, Pp 110-115 (2016)
The efficacy of naftidrofuryl in treating cerebrovascular diseases is analyzed on the basis of a review of the Russian and foreign literature. Naftidrofuryl is a seroton 5-HT2 receptor antagonist and acts on brain energy metabolism mainly during hypo
Externí odkaz:
https://doaj.org/article/0db37d0636f44f778d59c461a6d71d92
Publikováno v:
Nevrologiâ, Nejropsihiatriâ, Psihosomatika, Vol 7, Iss 4, Pp 110-115 (2016)
The efficacy of naftidrofuryl in treating cerebrovascular diseases is analyzed on the basis of a review of the Russian and foreign literature. Naftidrofuryl is a seroton 5-HT2 receptor antagonist and acts on brain energy metabolism mainly during hypo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6f539a3390c3ccef95c3b34f0c3279a
https://doi.org/10.14412/2074-2711-2015-4-110-115
https://doi.org/10.14412/2074-2711-2015-4-110-115